CDK4 Inhibition With Palbociclib in MCL

Video

In Partnership With:

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma.

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma (MCL).

The CDK4/6 inhibitor palbociclib has been shown to overcome ibrutinib (Imbruvica) resistance in primary human samples and MCL cell lines with the mutated BTKC481S protein. Targeting CDK4 is a rational approach in MCL, says Chen-Kiang, as dysregulation of CDK4 and cyclin D1 underlies unrestrained proliferation of MCL cells.

In a phase I clinical trial of 6 patients, palbociclib was administered to patients with MCL for 12 days, and bortezomib (Velcade) was given in prolonged early G1 arrest after synchronous S phase reentry. One patient progressed and 1 patient has been in complete remission for 6 years, suggesting that CDK4 inhibition reprograms MCL for therapy vulnerability. The follow-up clinical trial combined palbociclib together with ibrutinib. The combination looked durable with low toxicity, and induced impressive complete responses by preliminary analysis, says Chen-Kiang.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD